

DeepTek.ai makes US FDA cleared CADe Chest X-Ray AI solution commercially available

13 December 2023 | News

DeepTek's AI solutions have already made a significant impact in India and the Asia-Pacific region

DeepTek.ai, a leading provider of artificial intelligence (AI) solutions for medical imaging, has announced the commercial availability of Augmento X-Ray, a one of its kind CADe Chest X-Ray AI solution powered by US FDA Cleared CXR AI, at the world's largest radiology conference - Radiology Society of North America's (RSNA) 109th Annual Meeting. Augmento X-Ray is designed to significantly reduce radiologist workload and improve the quality of chest X-ray reporting.

Chest radiography is the most common medical imaging tool used in routine clinical practices to identify different disease findings. With 3.5 billion annual X-rays performed, 1.5 billion dedicated to chest examinations, the need for precise interpretation is critical.

Pune-based startup DeepTek's AI solutions have already made a significant impact in India and the Asia-Pacific region, transforming healthcare by increasing access to quality care at a lower cost.

The company's products are deployed in over 500 hospitals and imaging centres, impacting the lives of over a million individuals every year. In Singapore, DeepTek's US FDA-approved platform, Augmento Enterprise, has been chosen as the national radiology AI platform, contributing to improved productivity and quality of care across public hospitals.

DeepTek.ai has about 200 members and has partners like TATA Capital, NTT DATA Japan and Shimadzu Asia Pacific.

As DeepTek.ai prepares to venture into the US market, the company is set to leverage its new product launch and US FDA approvals to make a significant impact on the global healthcare landscape.